Evidence map›Paper›PMID 35280784›Full record

ArticleFrontiers in oncology2022

A Predictive Nomogram for Early Death in Pheochromocytoma and Paraganglioma.

Huiyang Li, Kirellos Said Abbas, Basel Abdelazeem, Yao Xu, Yile Lin, Haixiao Wu, Vladimir P Chekhonin, Karl Peltzer, Chao Zhang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Prognosis and tumor microenvironment in pseudohypoxic pheochromocytoma/paraganglioma.Virchows Archiv : an international journal of pathology · 2025
    Article
  3. Article
  4. Case Series:Frontiers in endocrinology · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 5 countries.

Huiyang LiDepartment of Obstetrics & Gynecology, Tianjin Medical University General Hospital, Tianjin, China.
Kirellos Said AbbasThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Basel AbdelazeemThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Yao XuThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Yile LinThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Haixiao WuThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Vladimir P ChekhoninThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Karl PeltzerThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Chao ZhangThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Tianjin Medical University Cancer Institute and Hospital · CNAlexandria University · EGFederal Medical Research Centre for Psychiatry and Narcology · RUMcLaren Health Care · USTianjin Medical University General Hospital · CNUniversity of the Free State · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pheochromocytoma (PHEO) and paraganglioma (PGL) are relatively rare neuroendocrine tumors. The factors affecting patients with early death remain poorly defined. We aimed to study the demographic and clinicopathologic pattern and to develop and validate a prediction model for PHEO/PGL patients with early death. Methods: Data of 800 participants were collected from the Surveillance Epidemiology and End Results (SEER) database as a construction cohort, while data of 340 participants were selected as a validation cohort. Risk factors considered included the year of diagnosis, age at diagnosis, gender, marital status, race, insurance status, tumor type, primary location, laterality, the presence of distant metastasis. Univariate and multivariate logistic regressions were performed to determine the risk factors. R software was used to generate the nomogram. Calibration ability, discrimination ability, and decision curve analysis were analyzed in both construction and validation cohorts. Results: PHEO and PGL patients accounted for 54.3% (N=434) and 45.7% (N=366), respectively. More than half of tumors (N=401, 50.1%) occurred in the adrenal gland, while 16.9% (N=135) were in aortic/carotid bodies. For the entire cohort, the median overall survival (OS) was 116.0 (95% CI: 101.5-130.5) months. The multivariate analysis revealed that older age ( Conclusions: We developed and validated a predictive nomogram utilizing data from the SEER database with satisfactory discrimination and calibration capability which can be used for early death prediction for PHEO/PGL patients.

Indexed as

early deathnomogramparagangliomapheochromocytomaSEER (surveillance epidemiology and end results) databasesurvival analysis

Identifiers

PMID35280784
PMCPMC8913719
OpenAlexW4214683907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.